News Conference News ACC 2023 Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA Yael L. Maxwell March 09, 2023
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2021 Complete Revascularization Analysis of ISCHEMIA Opens ‘Pandora’s Box’ Michael O'Riordan May 18, 2021
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News ACC 2020 More Symptoms, Less Extensive Disease in Women With Stable CAD: ISCHEMIA Michael O'Riordan March 28, 2020
News Conference News ACC 2018 Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues Michael O'Riordan March 11, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions Caitlin E. Cox March 18, 2017
News Conference News ACC 2015 Outcomes at 5 Years Reinforce Durability of Stenting for Unprotected Left Main Disease L.A. McKeown March 15, 2015
News Conference News ACC 2012 Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES Jason Kahn March 24, 2012